Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have not even released the PR yet LOL. Guessing Tuesday since mkt closed. so much coverage coming.
you are on the right track here
hearing prob a bit sooner on that so lets see. so many big events about to be announced.
yep. I emailed the company and got virtually the same response. BIG
IRB APPROVAL CONFIRMED - I emailed OWCP and confirmed. This is great news folks!
.50? Higher my friend.
Could happen. Lots of catalysts in play here that will be announced soon and this 8k is big. Lots of new eyes here. Congrats longs
IRB (FDA equivalent) APPROVAL done
It is APPROVED!!!!
Yep! Just read it! Huge huge huge
Can somebody please summarize the 8k? I cannot read right now. What's the gist???
no inside info at all. zero. anyone who does their DD can see where this is going. and more digging gives you a lot more info.
5 million shares. that is what they own. I have about 915k
Doesn't trade the stock. no reason to. Told me not to sell anything below $5. bought and is long term holder. why would he trade it if it is going MUCH higher? He's no dummy. take care.
nothing illegal about it. just an opinion based on trading etc... putting it all together.
yep. doors are open
I added shares since then. at $1.10 I am there. Going much higher than that though. $1 will be a joke.
I don't ask those questions and don't want to know. Don't need to know. When it happens it will happen and it will be huge. and all indications are it is any day any minute. the co did say january right?? this all adds up
from my guy at ML:
"expect huge update today - tomorrow"
fingers are crossed. Gotta be the IRB approval right????
The Largest Federal Appeals Court Tells DOJ To Back Off State-Legal Medical Marijuana - Huffington Post | Santa Cruz NORML
http://santacruznorml.org/the-largest-federal-appeals-court-tells-doj-to-back-off-state-legal-medical-marijuana-huffington-post/
not with the news that is coming
Pot Industry Exhales (a Little) After Trump’s Attorney General Pick Testifies
One cannabis investor called Jeff Sessions’ confirmation hearing a “huge victory.” Others were more measured.
by Polly Mosendz
January 12, 2017, 5:00 AM CST
When Donald Trump appointed Jeff Sessions as attorney general, the cannabis industry let out a collective groan. This week the industry, which is expected to balloon to $50 billion by 2026, got a hint of reprieve after Sessions was questioned about marijuana policy during his confirmation hearing.
One cannabis investor went so far as to call the hearing a "huge victory." Others in the industry expressed cautious optimism.
Sessions has called pot "a danger" and has long opposed legalization. "Good people don't smoke marijuana," he said last year at a Senate hearing. In an infamous quote attributed to Sessions in the 1980s, while he was being considered for a federal district judge position, he said he thought the Ku Klux Klan "were OK until I found out they smoked pot." He later apologized and said he was joking.
But the conservative Republican senator from Alabama is also a proponent of states' rights, and more than half of the states in the U.S. have legalized some form of cannabis, despite federal laws prohibiting its sale and consumption.
In his hearing, Sessions said he wouldn't "commit to never enforcing federal law" but added that "absolutely it's a problem of resources for the federal government." Recently, a spokesman for the Drug Enforcement Administration told Bloomberg that, given the growing opioid crisis, agents can't dedicate resources to monitor or curtail the distribution and use of cannabidiol products, which are technically controlled substances.
"It is notable that Sen. Sessions chose not to commit to vigorously enforcing federal prohibition laws in states that have reformed their marijuana laws," Robert Capecchi, director of federal policies for the Marijuana Policy Project, a cannabis legalization lobbying organization, said in an emailed statement. "He also recognized that enforcing federal marijuana laws would be dependent upon the availability of resources, the scarcity of which poses a problem. He was given the opportunity to take an extreme prohibitionist approach, and he passed on it."
Troy Dayton, co-founder of the Arcview Group, an Oakland, Calif.-based cannabis industry investment firm, went further, saying by email that the senator "left the door open but indicated it would be a low priority. That's a huge victory considering [Sessions'] previous inflammatory statements about this topic."
Dayton said Sessions "may be against marijuana policy reform, but he is not stupid. He knows that these cannabis laws are hugely popular, not just among Americans in red and blue states, but with his boss who campaigned in favor of these laws."
While his responses, on their face, were hardly a coup for the cannabis industry, Sessions didn't morally condemn pot smokers either.
"The United States Congress has made the possession of marijuana in every state, and distribution of it, an illegal act," he testified. "If that ... is not desired any longer, Congress should pass a law to change the rule."
The Drug Policy Alliance, an organization opposed to the war on drugs, called the testimony "wishy-washy at best." The group's senior director of national affairs, Bill Piper, added: "It is clear that he was too afraid to say the ‘reefer madness’ things he said just a year ago, and that’s progress. But he made it clear throughout the hearing that he will enforce federal law."
Your cheat sheet on life, in one weekly email.
Get our weekly Game Plan newsletter.
Enter your email
Sign Up
The National Cannabis Industry Association supported Sessions' deferral to Congress. "It's time for federal lawmakers to represent the clear choices of their constituents," Executive Director Aaron Smith said in an emailed statement. "The responsible cannabis industry has helped countless critically ill patients, contributed billions of dollars to the economy and to tax coffers, taken marijuana out of the criminal market and put it behind a regulated counter, and dealt a significant blow to international cartels and traffickers."
Sessions' remarks on pot aren't far off from what Attorney General Loretta Lynch—who hasn't pursued litigation against states that legalized cannabis consumption—said during her confirmation hearing in 2015.
"It certainly would be my policy, if confirmed as attorney general, to continue enforcing the marijuana laws, particularly with respect to the money laundering aspect of it," she said when questioned by Republican Senator Lindsey Graham. "Where we see the evidence that marijuana, as I've noticed in cases in my own district, brings with it not only organized crime activity but great levels of violence."
Before it's here, it's on the Bloomberg Terminal. LEARN MORE
by Taboola Sponsored Links From The Web
Here's Why Everyone's Obsessed With These Socks
Cup of Jo for Bombas Socks
"slippers for people who don't do slippers" - WIRED
mahabis.com
How To Fix Your Fatigue (Do This Every Day)
Vital Reds Supplement
A Radical Solution to the Dead Mall Phenomenon?
FTI Journal
How Car Dealers Get Rid of Unsold Inventory
Auto Deals Ace
Historic Photos That Been Withheld From The Public
HistoryInOrbit.com
Read This Next
Lacing Dog Treats With Cannabis Is Big Business
Weed Votes Are Already Boosting Warehouse Rents
America’s Legal Pot Economy Is Forced Underground
The Future of Cannabis Sales Is Tiny Brownies
Trump Team Said to Cancel Mattis House Panel Testimony on Waiver
by Roxana Tiron and Billy House
January 11, 2017, 2:27 PM CST
Defense secretary pick had agreed to testify at Armed Services
Cancellation said to be ordered by Trump transition team
BEDMINSTER TOWNSHIP, NJ - NOVEMBER 19: (L to R) President-elect Donald Trump welcomes retired United States Marine Corps general James Mattis as they pose for a photo before their meeting at Trump International Golf Club, November 19, 2016 in Bedminster Township, New Jersey. Trump and his transition team are in the process of filling cabinet and other high level positions for the new administration. Photographer: Drew Angerer/Getty Images
A House panel abruptly canceled a scheduled appearance by defense secretary nominee General James Mattis ahead of a vote to waive a law barring recently retired military officers from leading the Pentagon.
The retired Marine Corps four-star general had agreed to testify Thursday before the House Armed Services Committee, even though that chamber doesn’t have a role in confirming presidential nominees.
The decision to cancel his appearance came from President-elect Donald Trump’s transition team, according to a congressional aide familiar with the matter.
House Democrats say many members of their party aren’t inclined to approve the waiver unless Mattis appears before the committee.
"The idea is that if we don’t hear from him, we aren’t voting for him," said Adam Smith of Washington, the top Democrat on the panel, who added that he will be urging fellow House Democrats to follow suit.
The Republican chairman of the panel, Mac Thornberry of Texas, couldn’t immediately be reached for comment on whether any House Republicans will withhold support for the waiver when the bill reaches the House floor for a vote. The panel is still scheduled to vote on the waiver Thursday, with a vote on the House floor expected Friday.
There was no immediate response from Trump transition team officials on why they asked for the Mattis appearance to be canceled.
Seven Years
Mattis retired from the Marine Corps in 2013, well short of the requirement that a military officer be retired for at least seven years to serve as Pentagon chief.
Before Mattis can be confirmed, the House and Senate have to pass legislation to grant him an exception to that law.
Mattis was expected to testify before the House Armed Services panel about the role of civilian leadership of the military. His appearance was going to follow his formal confirmation hearing before the Senate Armed Services Committee Thursday morning.
While Mattis, 66, is still expected to win confirmation -- and the waiver legislation could win passage in the House and Senate this week -- the precedent being set worries some members.
Considering Consequences
“This requirement has served our nation well for the past 70 years, and only once has Congress waived or modified” it, Jack Reed of Rhode Island, the top Democrat on the Senate Armed Services Committee, said at a hearing Tuesday on the waiver.
“I believe it is extremely important that we carefully consider the consequences of setting aside the law” and “the implications such a decision may have on the future of civilian and military relations,” he added.
New York Democratic Senator Kirsten Gillibrand has said that while she respects Mattis, she won’t back a waiver.
The House’s No. 2 Democrat, Steny Hoyer of Maryland, told reporters Wednesday he believes "the committee has a right and a responsibility to inquire of General Mattis why he thinks there ought to be a waiver, what the ramifications of a waiver are, and what importance he thinks the seven-year waiting period has."
"Now, having said that, I want to make it clear I think most Democrats think General Mattis may well be the best appointee to the Cabinet that Trump has made," Hoyer said.
But, he added, "This is not a decision that should be lightly made."
https://www.bloomberg.com/news/articles/2017-01-12/pot-industry-exhales-a-little-after-trump-s-attorney-general-pick-testifies
DOW JONES NEWS - OWCP DOW JONES NEWS - Cannabis Stocks Positioning to Regain Momentum in 2017 | Dow Jones
PALM BEACH, Florida, January 12, 2017 /PRNewswire/ --
With the cannabis industry well-established as a serious player within the global economy, mergers and acquisitions are propelling the rapidly developing market to even higher heights. Cannabis operators in the markets this week include: Marapharm Ventures Inc. (OTC: MRPHF), MassRoots, Inc. (OTC: MSRT), OWC Pharmaceutical Research Corp. (OTC: OWCP), AXIM Biotechnologies, Inc. (OTC: AXIM) and 22nd Century Group, Inc. (NYSE: XXII).
Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) announced earlier this week plans to invests in Veritas Pharma Inc. Today Marapharm announces that is has entered into a subscription agreement to acquire 5 million 18 month $0.30 share purchase warrants of Veritas Pharma Inc. for consideration of $250,000. Read the full Marapharm press release and other news at: http://marketnewsupdates.com/news/mrphf.html
"We like the Veritas Pharma business model and we know that we can play a big role in their growth. Marapharm has acquired shares and rights to acquire up to 15 million shares of Veritas, after taking into account 10 million share purchase warrants that we have. As a result of the investment, Marapharm will have the right to appoint members to the Veritas board of directors. There's great synergy with Veritas and Marapharm and the additional investment in the share purchase warrants will provide additional capital to Veritas as they execute on their business plan," says Linda Sampson, Marapharm CEO.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances.
In other cannabis industry news and performances of note:
MassRoots, Inc. (OTCQB: MSRT), one of the leading technology platforms for the cannabis industry, announced it has received over $2.0 million in cash proceeds from the exercise of warrants so far in 2017. This gives MassRoots its strongest cash position in corporate history as it continues to capitalize on the expanding regulated cannabis market.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) closed up over 26% on Wednesday at $0.37 trading over 10.2 Million shares by the market close. OWC Pharmaceutical Research Corp. engages in the research and development of Cannabis-based medical products.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) closed up over 27% on Wednesday at $15 per share. Medical Marijuana, Inc. announced earlier this wekk that its major investment company AXIM(R) Biotechnologies, Inc. has received positive pharmacokinetic (PK) data results on its CanChew Plus(R) CBD Gum, which will be used in upcoming clinical trials with patients suffering from irritable bowel syndrome (IBS).
22nd Century Group, Inc. (NYSE: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, reported this week that the U.S. Food and Drug Administration (FDA) has provided the Company with helpful and positive feedback on the Company's combined Modified Risk Tobacco Product Applications (MRTPAs) and Premarket Tobacco Product Applications (PMTAs) for 22nd Century's "BRAND A" Very Low Nicotine tobacco cigarettes.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Marapharm Ventures Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com
Tel: (561)325-8757
SOURCE MarketNewsUpdates.com
> Dow Jones Newswires
January 12, 2017 08:30 ET (13:30 GMT)
Already have
IRB approval (FDA equivalent) will be announced any day and should take us much much higher. Could see $1 very soon.
you got it. I think it is kinda funny some people getting excited about hitting .35-.40 since this is going much higher. but hey....I am excited too. Will be multiple dollars very soon.
sharing from my guy at merrill lynch. Have a good day folks.
---------- Forwarded message ----------
From: xxxxxxxxxx@ml.com>
Date: Wed, Jan 11, 2017 8:17 AM
Subject: RE: ur welcome
All I can tell you is you will be damn happy very very soon. Don't even think about selling anything under $5. Would regret it forever. The next 3 months so many game chg announcements. our team over 5 million shares. Dinner on UUUUUUU
My guy at Merrill Lynch who got me into this told me the money behind this and coming into this is massive. anybody short won't be very happy.
does Not affect us. We are MEDICAL MJ. WE are gonna be great here.
Should easily break .25 this week
yep, and thanks for the 17's! Have a good day folks.
I selfishly want this to dip to .17 or .16 so I can buy more. Want another 75-100K.
I have 640k at .1211 avg.
I've got $80k invested in OWCP. Why is that hard to believe????
there is zero reason for this stock price to drop. In 2-3-4 weeks we will be much higher.
We are getting a huge update from the company tomorrow or Thursday per my source. It is just the start to more news - updates over the next few weeks. Congrats longs....we are going to finally be rewarded here in the next few weeks. And in a big big way. Mark this post.
We are getting a huge update from the company tomorrow or Thursday per my source. It is just the start to more news - updates over the next few weeks. Congrats longs....we are going to finally be rewarded here in the next few weeks. And in a big big way. Mark this post.
The Cream will rise to the top today
no trades so far today?
shorting this stock is NOT SMART. News could come at any time.